Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer

The aim of the current study was to determine the incidence, clinical presentation, and treatment outcomes of "bone-only metastases" in patients with breast cancer and to analyze the impact of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status on prognosis. Be...

Full description

Saved in:
Bibliographic Details
Published inCancer research and treatment Vol. 43; no. 2; pp. 89 - 95
Main Authors Lee, Su Jin, Park, Silvia, Ahn, Hee Kyung, Yi, Jun Ho, Cho, Eun Yoon, Sun, Jong Mu, Lee, Jeong Eon, Nam, Seok Jin, Yang, Jung-Hyun, Park, Yeon Hee, Ahn, Jin Seok, Im, Young-Hyuck
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Cancer Association 01.06.2011
대한암학회
Subjects
Original
의약학
Estrogen receptors
Breast neoplasms
Bone
HER2
Neoplasm metastasis
Progesterone receptors
Online AccessGet full text
ISSN1598-2998
2005-9256
2005-9256
DOI10.4143/crt.2011.43.2.89

Cover

Abstract The aim of the current study was to determine the incidence, clinical presentation, and treatment outcomes of "bone-only metastases" in patients with breast cancer and to analyze the impact of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status on prognosis. Between 1994 and 2007, of 968 patients with metastatic breast cancer who underwent palliative management at Samsung Medical Center, 565 (57%) relapsed with distant metastases. Of the 968, 146 (15%) had bone-only metastases during a median follow-up period of 75 months. Among the 146 patients with bone-only metastases, 122 (84%) were relapsed patients after curative surgery and 24 (26%) were initially metastatic cases. The median time from primary surgery to bone-only metastases of the 122 patients was 37 months (95% confidence interval [CI], 27 to 46 months). Bone-only metastases were more common in the HR-positive group than in the other subtypes (85% for HR+; 8.2% for HER2+; 6.8% for triple negative. Among all 146 patients, 75 (51%) were treated with hormone therapy. The median post-relapse progression-free survival was 15 months (95% CI, 13 to 17 months). The median overall survival was much longer in the HR+ patients than the HER2+ and triple negative breast cancer patients with marginal statistical significance (65 vs. 40 vs. 40 months, p=0.077). Breast cancer patients with "bone-only metastases" had excellent clinical outcomes. Further study is now warranted to reveal the underlying biology that regulates the behavior of this indolent tumor, as it should identify 'favorable tumor characteristics' in addition to 'favorable preferential metastatic site.'
AbstractList Purpose The aim of the current study was to determine the incidence, clinical presentation, and treatment outcomes of “bone-only metastases” in patients with breast cancer and to analyze the impact of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2)status on prognosis. Materials and Methods Between 1994 and 2007, of 968 patients with metastatic breast cancer who underwent palliative management at Samsung Medical Center, 565 (57%) relapsed with distant metastases. Of the 968, 146 (15%) had bone-only metastases during a median follow-up period of 75 months. Among the 146 patients with bone-only metastases, 122 (84%) were relapsed patients after curative surgery and 24 (26%) were initially metastatic cases. Results The median time from primary surgery to bone-only metastases of the 122 patients was 37months (95% confidence interval [CI], 27 to 46 months). Bone-only metastases were more common in the HR-positive group than in the other subtypes (85% for HR+; 8.2% for HER2+;6.8%for triple negative. Among all 146 patients, 75 (51%) were treated with hormone therapy. The median post-relapse progression-free survival was 15 months (95%CI, 13 to 17 months). The median overall survival was much longer in the HR+ patients than the HER2+ and triple negative breast cancer patients with marginal statistical significance (65 vs. 40 vs. 40months, p=0.077). Conclusion Breast cancer patients with “bone-only metastases” had excellent clinical outcomes. Further study is now warranted to reveal the underlying biology that regulates the behavior of this indolent tumor, as it should identify ‘favorable tumor characteristics’ in addition to ‘favorable preferential metastatic site.’ KCI Citation Count: 7
The aim of the current study was to determine the incidence, clinical presentation, and treatment outcomes of "bone-only metastases" in patients with breast cancer and to analyze the impact of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status on prognosis.PURPOSEThe aim of the current study was to determine the incidence, clinical presentation, and treatment outcomes of "bone-only metastases" in patients with breast cancer and to analyze the impact of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status on prognosis.Between 1994 and 2007, of 968 patients with metastatic breast cancer who underwent palliative management at Samsung Medical Center, 565 (57%) relapsed with distant metastases. Of the 968, 146 (15%) had bone-only metastases during a median follow-up period of 75 months. Among the 146 patients with bone-only metastases, 122 (84%) were relapsed patients after curative surgery and 24 (26%) were initially metastatic cases.MATERIALS AND METHODSBetween 1994 and 2007, of 968 patients with metastatic breast cancer who underwent palliative management at Samsung Medical Center, 565 (57%) relapsed with distant metastases. Of the 968, 146 (15%) had bone-only metastases during a median follow-up period of 75 months. Among the 146 patients with bone-only metastases, 122 (84%) were relapsed patients after curative surgery and 24 (26%) were initially metastatic cases.The median time from primary surgery to bone-only metastases of the 122 patients was 37 months (95% confidence interval [CI], 27 to 46 months). Bone-only metastases were more common in the HR-positive group than in the other subtypes (85% for HR+; 8.2% for HER2+; 6.8% for triple negative. Among all 146 patients, 75 (51%) were treated with hormone therapy. The median post-relapse progression-free survival was 15 months (95% CI, 13 to 17 months). The median overall survival was much longer in the HR+ patients than the HER2+ and triple negative breast cancer patients with marginal statistical significance (65 vs. 40 vs. 40 months, p=0.077).RESULTSThe median time from primary surgery to bone-only metastases of the 122 patients was 37 months (95% confidence interval [CI], 27 to 46 months). Bone-only metastases were more common in the HR-positive group than in the other subtypes (85% for HR+; 8.2% for HER2+; 6.8% for triple negative. Among all 146 patients, 75 (51%) were treated with hormone therapy. The median post-relapse progression-free survival was 15 months (95% CI, 13 to 17 months). The median overall survival was much longer in the HR+ patients than the HER2+ and triple negative breast cancer patients with marginal statistical significance (65 vs. 40 vs. 40 months, p=0.077).Breast cancer patients with "bone-only metastases" had excellent clinical outcomes. Further study is now warranted to reveal the underlying biology that regulates the behavior of this indolent tumor, as it should identify 'favorable tumor characteristics' in addition to 'favorable preferential metastatic site.'CONCLUSIONBreast cancer patients with "bone-only metastases" had excellent clinical outcomes. Further study is now warranted to reveal the underlying biology that regulates the behavior of this indolent tumor, as it should identify 'favorable tumor characteristics' in addition to 'favorable preferential metastatic site.'
The aim of the current study was to determine the incidence, clinical presentation, and treatment outcomes of "bone-only metastases" in patients with breast cancer and to analyze the impact of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status on prognosis. Between 1994 and 2007, of 968 patients with metastatic breast cancer who underwent palliative management at Samsung Medical Center, 565 (57%) relapsed with distant metastases. Of the 968, 146 (15%) had bone-only metastases during a median follow-up period of 75 months. Among the 146 patients with bone-only metastases, 122 (84%) were relapsed patients after curative surgery and 24 (26%) were initially metastatic cases. The median time from primary surgery to bone-only metastases of the 122 patients was 37 months (95% confidence interval [CI], 27 to 46 months). Bone-only metastases were more common in the HR-positive group than in the other subtypes (85% for HR+; 8.2% for HER2+; 6.8% for triple negative. Among all 146 patients, 75 (51%) were treated with hormone therapy. The median post-relapse progression-free survival was 15 months (95% CI, 13 to 17 months). The median overall survival was much longer in the HR+ patients than the HER2+ and triple negative breast cancer patients with marginal statistical significance (65 vs. 40 vs. 40 months, p=0.077). Breast cancer patients with "bone-only metastases" had excellent clinical outcomes. Further study is now warranted to reveal the underlying biology that regulates the behavior of this indolent tumor, as it should identify 'favorable tumor characteristics' in addition to 'favorable preferential metastatic site.'
Author Sun, Jong Mu
Ahn, Hee Kyung
Park, Silvia
Yi, Jun Ho
Nam, Seok Jin
Park, Yeon Hee
Im, Young-Hyuck
Cho, Eun Yoon
Ahn, Jin Seok
Lee, Su Jin
Yang, Jung-Hyun
Lee, Jeong Eon
AuthorAffiliation 2 Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
1 Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
3 Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
AuthorAffiliation_xml – name: 3 Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
– name: 1 Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
– name: 2 Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Author_xml – sequence: 1
  givenname: Su Jin
  surname: Lee
  fullname: Lee, Su Jin
– sequence: 2
  givenname: Silvia
  surname: Park
  fullname: Park, Silvia
– sequence: 3
  givenname: Hee Kyung
  surname: Ahn
  fullname: Ahn, Hee Kyung
– sequence: 4
  givenname: Jun Ho
  surname: Yi
  fullname: Yi, Jun Ho
– sequence: 5
  givenname: Eun Yoon
  surname: Cho
  fullname: Cho, Eun Yoon
– sequence: 6
  givenname: Jong Mu
  surname: Sun
  fullname: Sun, Jong Mu
– sequence: 7
  givenname: Jeong Eon
  surname: Lee
  fullname: Lee, Jeong Eon
– sequence: 8
  givenname: Seok Jin
  surname: Nam
  fullname: Nam, Seok Jin
– sequence: 9
  givenname: Jung-Hyun
  surname: Yang
  fullname: Yang, Jung-Hyun
– sequence: 10
  givenname: Yeon Hee
  surname: Park
  fullname: Park, Yeon Hee
– sequence: 11
  givenname: Jin Seok
  surname: Ahn
  fullname: Ahn, Jin Seok
– sequence: 12
  givenname: Young-Hyuck
  surname: Im
  fullname: Im, Young-Hyuck
BackLink https://www.ncbi.nlm.nih.gov/pubmed/21811424$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001564527$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp1kk1vEzEQhi1URNPCnRPyDS4b_LW7NgekNmpppKJUVTlbXmeWmu7awXYC_RP8ZpykVBQJydL4432fscdzhA588IDQa0qmggr-3sY8ZYTSqeBTNpXqGZowQupKsbo5QBNaK1kxpeQhOkrpGyGN4C19gQ4ZlZQKJibo13xcDc6a7IJPOPT4tGSoFn64x58hm1QGJOw8Po1QVnhmvIX4AZ-bTYimGwBfReghQtnGP1y-xWc_LQwD-IwX62zDCDvsRYhjIeNrsLDKIeKrkFx2G3gKfome92ZI8OohHqMv52c3s4vqcvFpPju5rKxgMlfQUckMXXLOpJS8rWthWMNJ19gaFGuYanvCm2bJDReWMsWk6VhnZdt3UlrKj9G7PdfHXt9Zp4Nxu_g16LuoT65v5prVom7qIv24l67W3QhLW14WzaBX0Y0m3u-MT0-8uy2YjeaUS8VYAbx9AMTwfQ0p69GlbY2Mh7BOWkpKZKu4KMo3f6d6zPHnu4qA7AU2hpRK4R8llOhtR-jSEXrbEbrMmZaqWJp_LNbl3XeXy7rh_8bf3Oy9Dw
CitedBy_id crossref_primary_10_3390_ijms24108488
crossref_primary_10_1016_j_clbc_2019_06_007
crossref_primary_10_1093_annonc_mdu558
crossref_primary_10_1097_MD_0000000000008985
crossref_primary_10_1172_JCI170953
crossref_primary_10_1038_s41422_023_00810_6
crossref_primary_10_1016_j_ejrad_2021_109821
crossref_primary_10_4236_abcr_2018_72008
crossref_primary_10_1007_s12609_023_00476_4
crossref_primary_10_1016_j_critrevonc_2020_103146
crossref_primary_10_1002_cam4_3597
crossref_primary_10_1016_j_rpor_2019_12_019
crossref_primary_10_1007_s10549_017_4529_5
crossref_primary_10_1155_2022_4123622
crossref_primary_10_1016_j_ejca_2020_11_044
crossref_primary_10_1007_s10549_020_05782_4
crossref_primary_10_3389_fcell_2020_00485
crossref_primary_10_1016_j_clbc_2014_09_009
crossref_primary_10_2147_CMAR_S369910
crossref_primary_10_4048_jbc_2013_16_1_66
crossref_primary_10_1016_S1470_2045_13_70209_2
crossref_primary_10_1016_j_biocel_2018_01_003
crossref_primary_10_1530_JME_16_0150
crossref_primary_10_1007_s12282_016_0730_3
crossref_primary_10_1016_j_ejso_2019_02_013
crossref_primary_10_1002_path_4882
crossref_primary_10_1007_s00520_016_3217_z
crossref_primary_10_1016_j_breast_2021_05_003
crossref_primary_10_1136_bmj_n98
crossref_primary_10_3390_curroncol30020108
crossref_primary_10_1007_s10549_018_4956_y
crossref_primary_10_1186_s12885_023_10729_1
crossref_primary_10_1016_j_clbc_2016_03_001
crossref_primary_10_1016_j_clbc_2019_11_004
crossref_primary_10_3390_cancers13061458
crossref_primary_10_1016_j_clbc_2017_05_012
crossref_primary_10_1016_j_ijpharm_2022_122092
crossref_primary_10_3390_cancers14235727
crossref_primary_10_1111_tbj_12808
crossref_primary_10_1038_s41416_018_0255_y
crossref_primary_10_1097_MS9_0000000000002270
crossref_primary_10_1016_j_jbo_2013_09_001
crossref_primary_10_1016_j_jbo_2018_01_004
crossref_primary_10_3919_jjsa_75_1484
crossref_primary_10_1371_journal_pone_0227256
crossref_primary_10_1038_s41467_019_12108_6
crossref_primary_10_2106_JBJS_RVW_22_00166
crossref_primary_10_3390_jcm11133589
crossref_primary_10_1007_s00404_016_4225_4
crossref_primary_10_1038_onc_2017_94
crossref_primary_10_2519_jospt_2020_9971
crossref_primary_10_1016_j_mednuc_2012_07_008
crossref_primary_10_1186_s12885_016_2345_7
crossref_primary_10_12968_bjon_2013_22_Sup7_S4
crossref_primary_10_1186_s13244_020_00885_4
crossref_primary_10_1016_j_tranon_2020_100993
crossref_primary_10_1007_s00259_023_06173_9
crossref_primary_10_3389_fbioe_2020_589964
crossref_primary_10_1002_ptr_8195
crossref_primary_10_1016_j_clbc_2014_06_007
crossref_primary_10_1634_theoncologist_2019_1006
crossref_primary_10_3233_PPR_170095
crossref_primary_10_1016_j_bone_2019_115139
crossref_primary_10_1016_j_bone_2020_115775
crossref_primary_10_1016_j_cpccr_2024_100292
crossref_primary_10_3390_biomedicines12051075
crossref_primary_10_1016_j_breast_2015_06_003
crossref_primary_10_1038_s41467_021_25473_y
crossref_primary_10_1186_s12885_023_11588_6
Cites_doi 10.1016/0002-9343(86)90286-X
10.1006/scbi.2001.0385
10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.3.CO;2-Z
10.1002/1097-0142(19860701)58:1<178::AID-CNCR2820580130>3.0.CO;2-T
10.1073/pnas.1331931100
10.1158/0008-5472.CAN-07-5644
10.3109/02841868809091774
10.1038/sj.onc.1208079
10.1111/j.1464-410X.2006.06194.x
10.1097/00005392-200108000-00096
10.1038/bjc.1987.13
10.1007/BF00050693
10.1016/S0140-6736(00)49915-0
10.1023/A:1022166517963
10.1056/NEJMra0805239
10.1677/ERC-06-0001
10.1038/bjc.1998.52
10.3322/canjclin.49.1.33
10.1038/nrg2101
10.1016/j.ccr.2009.05.017
10.1093/jnci/91.1.80
ContentType Journal Article
Copyright Copyright © 2011 by the Korean Cancer Association 2011
Copyright_xml – notice: Copyright © 2011 by the Korean Cancer Association 2011
DBID AAYXX
CITATION
NPM
7X8
5PM
ACYCR
DOI 10.4143/crt.2011.43.2.89
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2005-9256
EndPage 95
ExternalDocumentID oai_kci_go_kr_ARTI_254565
PMC3138922
21811424
10_4143_crt_2011_43_2_89
Genre Journal Article
GroupedDBID ---
29B
5-W
53G
8JR
9ZL
AAYXX
ACYCR
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
C1A
CITATION
DIK
E3Z
EF.
F5P
HYE
OK1
RPM
TR2
ABDBF
ACUHS
EBD
NPM
7X8
5PM
ID FETCH-LOGICAL-c428t-eb182a1d33288837554a2630b6c5e926297f0366d3a34c12928ab2bc87fb88c13
ISSN 1598-2998
2005-9256
IngestDate Sun Mar 09 07:51:33 EDT 2025
Thu Aug 21 13:50:13 EDT 2025
Fri Jul 11 09:32:15 EDT 2025
Thu Apr 03 07:01:36 EDT 2025
Tue Jul 01 03:18:42 EDT 2025
Thu Apr 24 23:11:38 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Estrogen receptors
Breast neoplasms
Bone
HER2
Neoplasm metastasis
Progesterone receptors
Language English
License This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c428t-eb182a1d33288837554a2630b6c5e926297f0366d3a34c12928ab2bc87fb88c13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
G704-000841.2011.43.2.005
http://kmbase.medric.or.kr/Main.aspx?d=KMBASE&m=VIEW&i=0939920110430020089
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC3138922
PMID 21811424
PQID 881087934
PQPubID 23479
PageCount 7
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_254565
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3138922
proquest_miscellaneous_881087934
pubmed_primary_21811424
crossref_primary_10_4143_crt_2011_43_2_89
crossref_citationtrail_10_4143_crt_2011_43_2_89
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2011-6-1
2011-Jun
20110601
2011-06
PublicationDateYYYYMMDD 2011-06-01
PublicationDate_xml – month: 06
  year: 2011
  text: 2011-6-1
  day: 01
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Cancer research and treatment
PublicationTitleAlternate Cancer Res Treat
PublicationYear 2011
Publisher Korean Cancer Association
대한암학회
Publisher_xml – name: Korean Cancer Association
– name: 대한암학회
References ref13
ref12
ref23
ref15
Carlson (ref9) 2009
ref14
ref20
ref11
ref22
ref10
ref2
ref1
ref17
ref16
ref19
ref18
ref8
(ref21) 2005
ref7
ref4
ref3
ref6
ref5
3814476 - Br J Cancer. 1987 Jan;55(1):61-6
9362426 - Cancer. 1997 Oct 15;80(8 Suppl):1588-94
17158753 - Endocr Relat Cancer. 2006 Dec;13(4):1033-67
12808139 - Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7737-42
9461007 - Br J Cancer. 1998;77(2):336-40
17440531 - Nat Rev Genet. 2007 May;8(5):341-52
12611463 - Breast Cancer Res Treat. 2003 Mar;78(1):105-18
18451135 - Cancer Res. 2008 May 1;68(9):3108-14
3219223 - Acta Oncol. 1988;27(6A):715-9
2423224 - Cancer. 1986 Jul 1;58(1):178-82
19200416 - J Natl Compr Canc Netw. 2009 Feb;7(2):122-92
19109576 - N Engl J Med. 2008 Dec 25;359(26):2814-23
19573813 - Cancer Cell. 2009 Jul 7;16(1):67-78
11458120 - J Urol. 2001 Aug;166(2):699-703
16686730 - BJU Int. 2006 Jun;97(6):1309-13
15894097 - Lancet. 2005 May 14-20;365(9472):1687-717
3893684 - Cancer Metastasis Rev. 1985;4(2):153-72
2673568 - Cancer Metastasis Rev. 1989 Aug;8(2):98-101
9890174 - J Natl Cancer Inst. 1999 Jan 6;91(1):80-5
15489913 - Oncogene. 2004 Oct 18;23(48):7957-68
11513565 - Semin Cancer Biol. 2001 Aug;11(4):297-306
10200776 - CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1
2428242 - Am J Med. 1986 Sep;81(3):381-6
References_xml – ident: ref5
  doi: 10.1016/0002-9343(86)90286-X
– ident: ref18
  doi: 10.1006/scbi.2001.0385
– ident: ref1
  doi: 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.3.CO;2-Z
– ident: ref4
  doi: 10.1002/1097-0142(19860701)58:1<178::AID-CNCR2820580130>3.0.CO;2-T
– ident: ref20
  doi: 10.1073/pnas.1331931100
– ident: ref11
  doi: 10.1158/0008-5472.CAN-07-5644
– ident: ref7
  doi: 10.3109/02841868809091774
– ident: ref23
  doi: 10.1038/sj.onc.1208079
– ident: ref16
  doi: 10.1111/j.1464-410X.2006.06194.x
– ident: ref17
  doi: 10.1097/00005392-200108000-00096
– ident: ref2
  doi: 10.1038/bjc.1987.13
– ident: ref6
  doi: 10.1007/BF00050693
– ident: ref14
  doi: 10.1016/S0140-6736(00)49915-0
– start-page: 122
  volume-title: Breast cancer: clinical practice guidelines in oncology
  year: 2009
  ident: ref9
– start-page: 1687
  volume-title: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
  year: 2005
  ident: ref21
– ident: ref22
  doi: 10.1023/A:1022166517963
– ident: ref12
  doi: 10.1056/NEJMra0805239
– ident: ref13
  doi: 10.1677/ERC-06-0001
– ident: ref8
  doi: 10.1038/bjc.1998.52
– ident: ref3
  doi: 10.3322/canjclin.49.1.33
– ident: ref10
  doi: 10.1038/nrg2101
– ident: ref19
  doi: 10.1016/j.ccr.2009.05.017
– ident: ref15
  doi: 10.1093/jnci/91.1.80
– reference: 9362426 - Cancer. 1997 Oct 15;80(8 Suppl):1588-94
– reference: 3893684 - Cancer Metastasis Rev. 1985;4(2):153-72
– reference: 2673568 - Cancer Metastasis Rev. 1989 Aug;8(2):98-101
– reference: 2423224 - Cancer. 1986 Jul 1;58(1):178-82
– reference: 10200776 - CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1
– reference: 11458120 - J Urol. 2001 Aug;166(2):699-703
– reference: 12611463 - Breast Cancer Res Treat. 2003 Mar;78(1):105-18
– reference: 9461007 - Br J Cancer. 1998;77(2):336-40
– reference: 19109576 - N Engl J Med. 2008 Dec 25;359(26):2814-23
– reference: 12808139 - Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7737-42
– reference: 3814476 - Br J Cancer. 1987 Jan;55(1):61-6
– reference: 19200416 - J Natl Compr Canc Netw. 2009 Feb;7(2):122-92
– reference: 18451135 - Cancer Res. 2008 May 1;68(9):3108-14
– reference: 17158753 - Endocr Relat Cancer. 2006 Dec;13(4):1033-67
– reference: 3219223 - Acta Oncol. 1988;27(6A):715-9
– reference: 15489913 - Oncogene. 2004 Oct 18;23(48):7957-68
– reference: 2428242 - Am J Med. 1986 Sep;81(3):381-6
– reference: 11513565 - Semin Cancer Biol. 2001 Aug;11(4):297-306
– reference: 17440531 - Nat Rev Genet. 2007 May;8(5):341-52
– reference: 15894097 - Lancet. 2005 May 14-20;365(9472):1687-717
– reference: 9890174 - J Natl Cancer Inst. 1999 Jan 6;91(1):80-5
– reference: 19573813 - Cancer Cell. 2009 Jul 7;16(1):67-78
– reference: 16686730 - BJU Int. 2006 Jun;97(6):1309-13
SSID ssj0064371
Score 2.1800184
Snippet The aim of the current study was to determine the incidence, clinical presentation, and treatment outcomes of "bone-only metastases" in patients with breast...
Purpose The aim of the current study was to determine the incidence, clinical presentation, and treatment outcomes of “bone-only metastases” in patients with...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 89
SubjectTerms Original
의약학
Title Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/21811424
https://www.proquest.com/docview/881087934
https://pubmed.ncbi.nlm.nih.gov/PMC3138922
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001564527
Volume 43
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Cancer Research and Treatment, 2011, 43(2), , pp.89-95
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLW6ISFeEN-ELxmJFxSlS5ykcXmbJlA3NIS0TdqblTgOjVaSqksmxo_ggV_MvXbiptVAwEsaOel1lXt6fa9zfEzIGz_jKilY6ilfMi_CNcDTJEs8GfOpn-M8pNbpPv40mZ1FR-fx-Wj0c8BaaptsLL_fuK7kf7wKbeBXXCX7D561RqEBzsG_cAQPw_GvfHw4pIND1pfVlfLqanGNG0OnkPddarqVmyHzvEGCl1R6W8givQLX46Kppd1nxEzJqm96Kh8JAm0Dv9lo0s4hswXbLoRHtYQq3TVcLyS-D00PM90D3eJ2YkJm_ZxltW_RgE5a96i0KP3c0bdPysVVaUeN_Xllhknlfrxuu_EWw1VpFpdU7qweTmEEA6rVWOlQp_VQp8xIjPdx2cg3dfhjgyBr9hzajv0RZH7gMLlqjDBrFI7ZePNWeMDLrxoLmNjgGr_1KGi5if2lHXKLQenh9zNAZnTH95yBed2NHe5td6fFpY2BjUxnp1oVNxUx21zcQXJzeo_c7aoSum8gdp-MVPWA3D7ueBcPyY8h0mhdUIs0ukYaLStq4EANHN5RizO6xhlFnFGLM9rjDM12OKM9zmiPs03Dj8jZh_enBzOv28nDk1DeNh4kBJylQR6GjHMeJpDDpmwS-tlExgoVK6dJAanUJA_TMJKQgjKeZiyTPCkyzmUQPia7FXT_FDUGJn4RRqooWBzlRZRGcR4GaSaTII_SgDlkr3_qQnYy97jbykJAuYsuE-AygS4TcM4Enzrkrf3G0ki8_OHe1-BIcSFLgbrs-PmlFhcrAdXnoWBYjsQOob2bBcRqfJppper2UnAe-BwGxMghT4zXbYc9aBySbODB3oDdbV6pyrmWgw-Ra8DYs9_afE7urP91L8hus2rVS0ilm-yVxvYvM1_PXw
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Implications+of+bone-only+metastases+in+breast+cancer%3A+favorable+preference+with+excellent+outcomes+of+hormone+receptor+positive+breast+cancer&rft.jtitle=Cancer+research+and+treatment&rft.au=Lee%2C+Su+Jin&rft.au=Park%2C+Silvia&rft.au=Ahn%2C+Hee+Kyung&rft.au=Yi%2C+Jun+Ho&rft.date=2011-06-01&rft.eissn=2005-9256&rft.volume=43&rft.issue=2&rft.spage=89&rft_id=info:doi/10.4143%2Fcrt.2011.43.2.89&rft_id=info%3Apmid%2F21811424&rft.externalDocID=21811424
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1598-2998&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1598-2998&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1598-2998&client=summon